2012 Prince Edward Island Family Physicians of the Year - Paul B. Kelly, MD, CCFP, FCFP
Dr Paul Kelly #39;s medical career has been focused in Atlantic Canada and includes an adventure to Botswana, Africa, where he volunteered as a physician for two years with Cuso International. A medical graduate of Dalhousie University, Dr Kelly received his Certification in Family Medicine in 1979 and became a Fellow of the College of Family Physicians of Canada (CFPC) in 2001. Dr Kelly began practising family medicine with the Newfoundland Cottage Hospital system in 1972. In 1977, after returning from Africa, he joined the Summerside Medical Centre in his home town, where he practised family medicine until 2001, then moved to a collaborative practice at the Harbourside Family Health Centre. Currently, Dr Kelly is Resource Physician to the Integrated Palliative Care Team with Prince County Hospital, where he has served as Chief of Staff and Head of Family Medicine. Dr Kelly #39;s commitment to family medicine has been recognized with several awards: the CFPC #39;s Award of Excellence in Palliative Care in 2006; the Tom Moore Award, Prince County Hospital in 2001; and the PEI Medical Society #39;s Health Promotion Award in 1994. Dr Kelly #39;s committee involvement includes roles with the PEI Medical Society Board, the Canadian Medical Association #39;s Council on Healthcare and Promotion, and the Council on Education and Workforce. He currently serves on the PEI Provincial Medical Advisory Committee. Dr Kelly enjoys spending time with his wife of 33 years, Katherine mdash;whom he met in Botswana ...From:CFPCMediaViews:2 0ratingsTime:02:21More inNonprofits Activism

See the rest here:

2012 Prince Edward Island Family Physicians of the Year - Paul B. Kelly, MD, CCFP, FCFP - Video

2012 Manitoba Family Physicians of the Year - Frances Berard, MD, CCFP, FCFP
Dr Frances Berard is honoured for her commitment to the provision of rural family medicine in the francophone community of Notre Dame de Lourdes, Manitoba. After receiving her medical degree from the University of Manitoba, Dr Berard completed her residency training at the Family Medical Centre of St. Boniface General Hospital in 1991. Dr Berard received Certification in Family Medicine in 1991 and became a Fellow of the College of Family Physicians of Canada (CFPC) in 2004. In 1991, Dr Berard began practising family medicine at the Kildonan Medical Centre in Winnipeg as a locum for a sabbatical leave. Since 1992, she has served as Chief of Staff at the Centre de sant Notre Dame, where she practises comprehensive family medicine, including hospital and emergency care, obstetrics, and long-term care. She also works at the Miami Medical Clinic, a satellite clinic in Miami, Manitoba. Currently, Dr Berard is Associate Director of the bilingual Family Medicine Program at the University of Manitoba. She is also a preceptor to second-year family medicine residents and bilingual medical students from all levels. For ten years, Dr Berard served as Practice Advisor to international medical graduates. In 2008, Dr Berard served as President of the Manitoba College of Family Physicians. She is a member of the CFPC #39;s Member Advisory Committee and the Hospital Medicine Committee, and is an instructor with the Advanced Life Support in Obstetrics (ALSO) Program. In all of her work, Dr ...From:CFPCMediaViews:1 0ratingsTime:02:29More inNonprofits Activism

Link:

2012 Manitoba Family Physicians of the Year - Frances Berard, MD, CCFP, FCFP - Video

2012 Alberta Family Physicians of the Year - Michel Donoff, MD, CCFP, FCFP
Dr Michel Donoff is recognized for his extensive contributions to family medicine practice, education, and patient advocacy through his work in the Department of Family Medicine at the University of Alberta. As a medical graduate from the University of Alberta, Dr Donoff received his Certification in Family Medicine in 1979. In 1998, he became a Fellow of the College of Family Physicians of Canada (CFPC). For 30 years, Dr Donoff has practised comprehensive family medicine, including obstetrics, at the Royal Alexandra Hospital Family Medicine Centre in Edmonton. He left his practice in 2006, but continues his role as Clinic Director of the Centre. At the University of Alberta, Dr Donoff is actively involved as Full Professor and Associate Chair of the Department of Family Medicine. He also serves as Co-Chair of the Edmonton Oliver Primary Care Network and has been involved with physician assessment, electronic medical record development, and quality improvement measures. Dr Donoff has served on several CFPC committees and as a consultant to the US Task Force on Competency Assessment in Family Medicine. He has also been instrumental in developing a Competency-Based Assessment System, a method that provides residents with focused feedback on performance in a number of domains. This system is being adopted by the College of Physicians and Surgeons of Alberta and piloted by a variety of Royal College specialty programs. Outside of work, Dr Donoff enjoys outdoor activities and ...From:CFPCMediaViews:1 0ratingsTime:02:24More inNonprofits Activism

Read more:

2012 Alberta Family Physicians of the Year - Michel Donoff, MD, CCFP, FCFP - Video

2012 Saskatchewan Family Physicians of the Year - Daniel Johnson, MD, CCFP, FCFP
Dr Daniel Johnson was nominated by his colleagues and medical residents for his outstanding commitment to family medicine throughout his 38-year career. Dr Johnson received his medical degree from the University of Saskatchewan in 1971 and completed his family medicine residency at St. Joseph #39;s Family Medical Centre at the University of Western Ontario in 1974. That same year, he received Certification in Family Medicine and became a Fellow of the College of Family Physicians of Canada in 2001. Dr Johnson began practising family medicine in Tyne Valley, PEI, in 1974. In 1975, he returned to Saskatchewan and began practising family medicine, with an interest in anaesthesia, at the Kindersley Clinic in Kindersley, Saskatchewan, where he continues to practise today. Among his many roles with the University of Saskatchewan, Dr Johnson serves as Clinical Associate Professor and Preceptor for medical students and residents. He also participates as an evaluator of local and international applicants applying to the family medicine program. Among his professional affiliations, Dr Johnson served as President of the Saskatchewan College of Family Physicians in 1982 and was a Board Member of the Saskatchewan Medical Association. Dr Johnson has been President of his local Kinsmen Club and President of the Kindersley Drug and Alcohol Abuse Society. In previous years, he coached swimming at the community swim club. In all of his work, Dr Johnson is supported by his wife Connie, son Neil ...From:CFPCMediaViews:1 0ratingsTime:02:29More inNonprofits Activism

See the article here:

2012 Saskatchewan Family Physicians of the Year - Daniel Johnson, MD, CCFP, FCFP - Video

2012 Quebec Family Physicians of the Year - Andre Gagnon, MD, CCFP
Dr Andre Gagnon is a compassionate family physician who has focused her career on newborn and maternity care. Dr Gagnon is a medical graduate from the University of Montreal. In 1992, she completed her residency training at Cit de la Sant de Laval and received her Certification in Family Medicine. Since 1992, Dr Gagnon has practised family medicine, including obstetrics, with the Htel-Dieu de Saint-Jrme and the Clinique Medicale St. Antoine in SaintJrme, Quebec. In 2001, she became Head of the Department of Perinatology with Htel-Dieu de Saint-Jrme and continues to specialize in prenatal, perinatal, and post-partum care, as well as in neonatal care and pediatrics. From 2001 to 2005, Dr Gagnon served as a family physician representative on the Regional Perinatal Committee of the Lower Laurentians, a group that integrated midwife services into obstetrical care at Htel-Dieu de Saint-Jrme. Dr Gagnon #39;s committee involvement includes the CFPC #39;s Maternity and Newborn Care Program Committee and the Canadian Paediatric Society #39;s Fetus and Newborn Committee, where she is the CFPC #39;s Quebec representative. Since 2009, she has been President of the Association des omnipraticiens en prinatalit du Qubec. In 2011, Dr Gagnon served as an expert on two projects mandated by the Quebec health minister. One focused on the reduction of unnecessary interventions in obstetrics, the other on enhancing accessibility to perinatal care in the Montreal area. Dr Gagnon participates in ...From:CFPCMediaViews:3 0ratingsTime:02:28More inNonprofits Activism

Excerpt from:

2012 Quebec Family Physicians of the Year - Andrée Gagnon, MD, CCFP - Video

Wellesley ER doctor causes violent Traffic Accident | Kristin Howard Drunk and On Drugs
A Wellesley doctor was charged with operating under the influence of drugs and alcohol after a violent crash near a supermarket in Wellesley. The crash happened at about 8:45 am on Nov. 9. Police said Kristin Howard, 56, drove her car from the Whole Foods parking lot, through bushes, over a sprinkler system, over a sidewalk and went airborne into traffic on State Street. Her car collided with another car waiting at a stop light. Video from a traffic camera in the area showed the force of the crash pushing the car into a truck hauling a trailer on the other side of the street. Police said before the crash Howard had backed into a fence at Whole Foods twice. One person was taken to the hospital with injuries. That person was treated and released. Police said Howard had been prescribing drugs to herself and pill bottles were found in the car following the crash. She was charged with operating under the influence of drugs and alcohol, negligent operation of a motor vehicle, leaving the scene of a property damage accident and possession of class E and C drugs. The Massachusetts medical board told Fox 25 that Howard is an emergency room doctor at Newton-Wellesley Hospital. The board said she has worked there for 13 years. She was told not to come to work following the crash. The board said it would decide what to do about Howard #39;s long-term career in medicine at some point Tuesday afternoon. Howard will appear in court again in January.From:5portsCenterViews:0 0ratingsTime:01:56More inNews Politics

More:

Wellesley ER doctor causes violent Traffic Accident | Kristin Howard Drunk and On Drugs - Video

Humans Getting Dumber As Species
A scientist claims humans are potentially getting dumber as a species. Are humans getting dumber as a species? Stanford University professor Gerald Crabtree #39;s research into human kind #39;s intelligence suggests that due to the low level of competition for basic necessities in the modern world, the best and brightest aren #39;t the only ones naturally selected for survival and procreation anymore. Civilization and modern medicine allow for even the dumbest and most physically unfit to survive and pass their genes on to the next generation. In the distant past, survival wasn #39;t so easy. The Darwinian concept of evolution dictates that only the people who could navigate the complexities of life on earth would be able to live on and provide for their offspring. Crabtree says: "New developments in genetics, anthropology, and neurobiology... make a clear prediction that our intellectual and emotional abilities are genetically surprisingly fragile." When comparing genomes of parents and their children, it turns out that there are somewhere between 25 and 65 DNA mutations between each generation. Other scientists oppose Crabtree #39;s ideas saying that there is no real way to test his theory. What do you think? Are humans getting dumber due to the conveniences of modern life?From:geobeatsViews:4 0ratingsTime:01:14More inEducation

Read the original post:

Humans Getting Dumber As Species - Video

Unnecessary Procedure 5.10a Medicine Wall San Antonio GoPro Hero 2 rock climbing (HD)
rock climbing Unnecessary Procedure 5.10a at medicine wall in san antonio texas this was filmed with a gopro hero 2 HD outdoor edition headcam Other rock climbing spots in south central texas include: Area 57 Barton Creek Greenbelt BLORA Blue Hole Bottle Cap Bucket Cave and the Grot Bull...From:TrevorManBearPigViews:2 0ratingsTime:05:45More inSports

More here:

Unnecessary Procedure 5.10a Medicine Wall San Antonio GoPro Hero 2 rock climbing (HD) - Video

real doctors real people - Joshua Berkowitz
Life for Josh Berkowitz, a third year resident in Internal Medicine / Pediatrics, is constantly at full speed. If he #39;s not with a patient at the hospital, in a clinic or with his family being a husband and father, then you #39;ll find him on the field competing in Ultimate Frisbee.From:uncmedicineViews:2 0ratingsTime:02:31More inEducation

View original post here:

real doctors real people - Joshua Berkowitz - Video

Dr. Judith McBean
Dr. Judith McBean is a obstetrician/gynecologist with Brattleboro Obstetrics and Gynecology (Brattleboro OBGYN) which is a member of BMH Physician Group located on the Brattleboro Memorial Hospital campus in the Gannett Building. Dr. McBean is board-certified in obstetrics, gynecology, reproductive endocrinology and infertility. She is a graduate of University of Vermont College of Medicine following which she completed her internship and residency, Medical Center Hospital, University of Vermont. http://www.bmhvt.org brattleboroobgyn.comFrom:BMHospitalViews:1 0ratingsTime:01:42More inNonprofits Activism

See the article here:

Dr. Judith McBean - Video

Effect of sanctions on the Iranian patients-Iran Today-11-13-2012
Thalassemia, Hemophilia, Hepatitis, Multiple Sclerosis, Diabetes, and different types of cancer are only some of the medical conditions affecting the human body which require special care. Patients suffering from these diseases usually struggle to receive the costly and ongoing medical treatment that they need. In Iran, the ordeal is even tougher. Such patients not only have to worry about keeping up with the increasing costs of their treatments but now as a result of tighter sanctions imposed by the US and the EU they also have to deal with the severe shortage of the medicine that they need. The medication these patients require is mostly produced in Europe and North America. Although the sanctions do not directly ban selling medicine and medical supplies to Iran, sanctions on the banking sector which have made banking transactions impossible are effectively hindering the import of medicine. Efforts made by the Iranian government to domestically produce these drugs have so far failed also because of raw material shortage in the pharmaceutical industry for the same reasons. In this edition of the show we will be looking into the nature of the US-led sanctions against Iran and the consequences of these sanctions on patients suffering from special medical conditions. Watch this video on our website: http://www.presstv.com Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.com Follow our Tumblr on: presstvchannel.tumblr.comFrom:PressTVGlobalNewsViews:1 0ratingsTime:25:55More inNews Politics

Visit link:

Effect of sanctions on the Iranian patients-Iran Today-11-13-2012 - Video

Unseen Medicine: Discovering Integrative Healing Modalities (2013) - Documentary Trailer
I received a "Special Thanks" credit for my involvement with this feature length documentary which explores various alternative medicine and healing approaches. Its director/producer, Christopher Essey, has worked on numerous projects in the industry including Boardwalk Empire, Jeremy Fink and the Meaning of Life, Goat and a film I produced called Mafia Man: Robstown Gangster.From:ronniecinemaViews:2 0ratingsTime:06:00More inFilm Animation

Read the original:

Unseen Medicine: Discovering Integrative Healing Modalities (2013) - Documentary Trailer - Video

YouAid: Doctor Stefano Barco at Mahuninga Hospital
Dr. Stefano Barco is an Italian MD from University of Pavia, specializing in Internal Medicine and Haemostasis Disease. Stefano spent three weeks in Mahuninga Health Center in September 2011 helping to improve the quality and the medical organization. He has created medical records for each patients for an appropriate management and follow-up; moreover, he organised the official medical registry of the hospital, donating also three new personal computers. Anna is a six-years-old child from Mahuninga village. In June 2011, due to a sudden fire in the village, Anna felt in the flames and reported burns on 40% of her body. Thanks to Mahuninga Health Center and its workers, she was immediately treated and saved from certain death, and now she is fine. During the three months say in the hospital as in-patient, Anna met Dr. Stefano and she was very interested in... his harmonica! follow us on: facebook.com/reteYouAid youaid.it contacts: retesolidaleyouaid@gmail.comFrom:YouAidTVViews:0 0ratingsTime:02:29More inNonprofits Activism

See original here:

YouAid: Doctor Stefano Barco at Mahuninga Hospital - Video

YouAid: Doctor Alice Trinchero at Mahuninga Hospital
Dr. Alice Trinchero is an Italian MD from University of Pavia, specializing in Internal Medicine and Haemostasis Disease. Alice spent three weeks in Mahuninga Health Center in December 2011 working side by side with the local staff. The efforts focused on the laboratory procedures, especially for what concern the diagnosis of malaria thanks to the new stains brought from Pavia. Thanks to the materials in the hospital and the knowledge shared between Alice and the "Sisters" , it was possible to face many difficult cases, in particular some cases of cerebral malaria, and treat them with great results. follow us on: facebook.com/reteYouAid youaid.it contacts: retesolidaleyouaid@gmail.com Music: I don #39;t own rights over it - fair useFrom:YouAidTVViews:0 0ratingsTime:04:19More inNonprofits Activism

Read this article:

YouAid: Doctor Alice Trinchero at Mahuninga Hospital - Video

13 November 2012 Last updated at 20:03 ET By Michelle Roberts Health editor, BBC News online

A global treaty to crack down on the deadly trade of fake medicines is urgently needed, say experts.

Currently, there are more sanctions around the use of illegal tobacco than counterfeit drugs.

Writing in the British Medical Journal, experts urge the World Health Organization to set up a framework akin to its one tobacco control to safeguard the public.

WHO says more than one in every 10 drug products in poorer nations are fake.

A third of malaria drugs are counterfeit, research suggests.

In richer countries, medicine safety is better, but substandard and falsified drugs still cause thousands of adverse reactions and some deaths.

Recently, in the US, contaminated drug supplies caused an outbreak of meningitis that has so far killed 16 people.

Amir Attaran and colleagues from the World Federation of Public Health Associations, International Pharmaceutical Federation and the International Council of Nurses, say while governments and drug companies alike deplore unsafe medicines, it is difficult to achieve agreement on action because discussions too often trespass into conflict-prone areas such as pharmaceutical pricing or intellectual property rights.

In Canada we have seen a fake version of the heart drug Avastin come into the country that contains no active drug, just starch and nail polish remover

Go here to read the rest:

Call for fake medicine crackdown

NASHVILLE, Tenn.--(BUSINESS WIRE)--

Healthways (HWAY) today announced a five-year extension of their decade-long agreement with Johns Hopkins Medicine (JHM) to leverage its clinical, research and educational capabilities in the rapid development, testing and distribution of new well-being improvement science and solutions. Johns Hopkins HealthCare Solutions (JHHCS), a division of Johns Hopkins HealthCare, will coordinate support of the joint effort by faculty and staff members of the institution.

As a leading provider of health and medical services to the population we serve and as a major employer, Johns Hopkins Medicine faces many of the same challenges confronting healthcare organizations worldwide, said JHHC President Patricia M. C. Brown, JD. Successfully meeting these challenges requires new solutions, new distribution and payment models, and new partnerships.

Our new agreement with Johns Hopkins reflects a major change in focus for our ongoing collaboration, noted Ben R. Leedle, Jr., Healthways president and CEO. Historically, we sought Hopkins support to validate our clinical pathways, validate our outcomes and provide support and guidance to our physician outreach efforts. As our relationship matured over the past decade, however, we came to recognize even greater opportunities that could be pursued by harnessing our unique capabilities to contribute to practical research into new approaches that would accelerate our respective abilities to address the health needs of each individual in the populations we serve, rather than just the care needs of those who are already sick.

The new agreement with JHM reflects Healthways' long-term commitment to developing and distributing programs based on sound clinical research, such as the joint market introduction of InnergyTM, the commercial version of the new standard of care weight-loss program validated by faculty of the Johns Hopkins University School of Medicine in the NIH-supported POWER1 trial concluded last year.

We have successfully tested this new model for collaboration through our participation in the POWER trial and the market introduction of Innergy, Leedle said. We now look forward with confidence to the development and distribution of new, even more effective models to engage individuals of all ages in the lifestyle and health behaviors that we know will contribute to their improved well-being, reduced health-related cost and improved performance.

The research, program development and distribution activities contemplated by the new agreement will be guided by a Joint Steering Committee (JSC) that includes clinical, research, program development and distribution experts from both JHM, JHHCS and Healthways. Chaired by Frederick L Brancati, MD, MHS, chair of the Division of General Internal Medicine at the Johns Hopkins University School of Medicine and the executive medical director of JHHCS, the Joint Steering Committee will set the agenda for, and guide, the workflows contemplated under the agreement. In addition, the JHHCS members of the JSC will provide ongoing oversight of all services provided to Healthways by JHM and its affiliates, and their respective faculty and staff, in support of the organizations mutual objectives.

It is increasingly clear that the role of health care professionals and institutions will be undergoing significant change in the face of burgeoning epidemics of lifestyle-dependent diseases and their contribution to unsustainable levels of cost both in the U.S. and overseas, Brancati said. The purpose of this agreement is to harness the unique capabilities of both organizations to accelerate the development and distribution of new solutions to effectively address those challenges.

About Healthways

Healthways is the largest independent global provider of well-being improvement solutions. Dedicated to creating a healthier world one person at a time, the Company uses the science of behavior change to produce and measure positive change in well-being for our customers, which include employers, integrated health systems, hospitals, physicians, health plans, communities and government entities. We provide highly specific and personalized support for each individual and their team of experts to optimize each participants health and productivity and to reduce health-related costs. Results are achieved by addressing longitudinal health risks and care needs of everyone in a given population. The Company has scaled its proprietary technology infrastructure and delivery capabilities developed over 30 years and now serves approximately 40 million people on four continents. Learn more at http://www.healthways.com.

Read more:

Healthways and Johns Hopkins Medicine Extend and Expand Decade-Long Agreement to Translate Clinical Research into ...

DALLAS and JACKSONVILLE, Fla., Nov. 14, 2012 /PRNewswire/ -- U.S. Preventive Medicine, Inc. (USPM) has announced plans to open a joint venture in Singapore to launch its global health movement in the Asian market. This new venture, Asia Preventive Medicine, is in tandem with USPM's global efforts in the United States, United Kingdom, United Arab Emirates and soon in India.

"Our global strategy is to take our clinically focused preventive medicine program known as The Prevention Plan, as well as our Macaw mobile application, worldwide," said Christopher Fey, USPM Chairman and CEO. "Singapore gives us the hub to launch into Asia and have the opportunity to offer more good years to several billion people."

USPM's expansion is directly in line with the company's mission to make the world a healthier place. Currently, Macaw, the health and fitness mobile app from USPM, has members in more than 20 countries, and USPM's Prevention Plan has members in all 50 states, Canada, Great Britain and the United Arab Emirates. The company's new joint venture in Singapore will allow USPM to reach a large population and provide clinically proven, technology-based solutions to help people take control of their health.

Dr. Ron Loeppke, M.D., FACPM, USPM Vice Chairman states, "The impact from the 'Silent Epidemics' of chronic illness (e.g. Obesity, Diabetes, Heart Disease, Cancer) is a critical global risk that is destructive and debilitating to individuals as well as nations. We and others have proven that wellness works and prevention pays. Our mission is to leverage the power of prevention to help make the world a healthier place."

About U.S. Preventive Medicine

U.S. Preventive Medicine (www.USPM.com) is a leading, cloud-based global preventive health movement focused on saving lives and money by keeping people healthy and better managing chronic conditions before they progress. Innovative products -- The Prevention Plan(TM) web-based health management platform and Macaw mobile health & fitness app -- are based on the clinical science of preventive medicine: primary (wellness and health promotion to keep healthy people healthy), secondary (screening for earlier detection/diagnosis) and tertiary (early evidence-based treatment to reduce complications and disability). The company is accredited in wellness and health promotion by NCQA (the National Committee for Quality Assurance) and disease management by URAC. More information can be found on Facebook (Facebook.com/ThePreventionPlan( http://www.facebook.com/ThePreventionPlan )), Twitter (@USPM( http://twitter.com/USPM )) and YouTube (YouTube.com/thepreventionchannel( http://www.youtube.com/thepreventionchannel )). Macaw is available for free download on iPhone and Android smartphones at http://www.MacawApp.com.

About The Prevention Plan

The Prevention Plan is a clinically proven, step-by-step health management program designed to help people take control of their health. Through a health appraisal and comprehensive blood test panel, The Plan identifies an individual's top health risks and designs a customized plan of action to reduce those risks. Each member is supported by health coaching, robust online tools, plan-wide challenges with rewards, and a dynamic Prevention ScoreSM to help them stay motivated and on track to improving their health. A study published in the peer-reviewed journal Population Health Management, "The Impact of The Prevention Plan on Employee Health Risk Reduction," (October 2010) demonstrated that The Prevention Plan is effective in achieving measurable improvements in key health risk factors after just one year on the plan. Recent findings show that after two years on The Prevention Plan, members significantly reduced health risks in 14 of 15 key risk areas.

About Macaw

Unlike other available health and fitness apps, Macaw is based on the clinical science of preventive medicine and is universally designed for people who exercise regularly as well as those who are novices when it comes to physical activity. Macaw transforms a smartphone into the ultimate personal health monitor, connecting an individual's health apps and wireless devices for tracking weight, fitness, overall activity and biometrics -- including pedometers, glucose meters, activity armbands, scales, labs, sleep managers, mobile weight loss apps and blood pressure cuffs -- into a single app for complete tracking. Macaw users are able to track their physical activity, nutrition, progress and health knowledge while engaging in games that unlock prizes.

Visit link:

U.S. Preventive Medicine To Open Singapore Operations Center To Launch Asia Preventive Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. and ARIAD Pharmaceuticals, Inc. (ARIA) today announced a genomic profiling collaboration to study AP26113, ARIADs investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIADs ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.

It is important that we have a deep molecular understanding of patients tumors as they begin treatment with AP26113, especially those patients with complex prior treatment histories, stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. Foundation Medicine is at the forefront of genomic profiling technologies that will provide molecular insights on a wide array of clinically relevant tumor genes including ALK and EGFR alteration status. We look forward to collaborating on the AP26113 program as we move into anticipated pivotal trial(s) in 2013.

This study is an example of how cancer complexity often defies single-marker analysis in drug development, said Michael Pellini, M.D., president and chief executive officer, Foundation Medicine. We expect that our comprehensive genomic profile will help to identify the optimal patient population for AP26113 and may potentially enable an expedited development timeline.

About ARIAD

ARIAD Pharmaceuticals, Inc.is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIADs approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.comor follow ARIAD onTwitter.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical product, FoundationOne, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.foundationmedicine.com.

Foundation Medicine is a registered trademark, and FoundationOne is a trademark, of Foundation Medicine, Inc.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20121113005372/en/

Go here to read the rest:

Foundation Medicine and ARIAD Announce Collaboration for Genomic Characterization of Patients in AP26113 Oncology ...

WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today reported financial results for the third quarter ended September 30, 2012 and provided a business update.

Total revenue increased to $0.6 million in the third quarter of 2012 compared to $0.2 million in the same period in 2011. Product revenue from the BGM Galectin-3(R) test was $0.6 million in the third quarter of 2012, compared to $0.1 million in the same period in 2011.

Operating expenses for the third quarter of 2012 increased by $2.1 million to $7.2 million compared to 2011. This increase was driven by an increase in research and development investment of $0.6 million related primarily to the CardioSCORE(TM) test program and by an increase in sales and marketing expense of $0.9 million to support commercialization of the BGM Galectin-3 test. General and administrative expenses increased $0.4 million primarily due to personnel related costs and public company related expenses.

Net loss for the quarter was $6.8 million compared with a loss of $4.9 million in the third quarter of 2011.

Basic and diluted net loss per share attributable to common shareholders was $(0.34) in the third quarter of 2012, compared with basic and diluted net income per share of $(0.25) for the same period of 2011.

At September 30, 2012, the Company had cash and cash equivalents totaling approximately $18.1 million compared to $24.4 million at December 31, 2011.

"Over the past quarter, we continued to make important progress with the BGM Galectin-3 test by augmenting U.S. sales and marketing efforts and expanding into other markets," said Eric Bouvier, president and chief executive officer of BG Medicine. "With our new corporate strategy and structure in place, we look forward to maximizing control over the commercial execution of the BGM Galectin-3 and CardioSCORE tests, which we believe will assist us to become a leader in delivering novel cardiovascular diagnostics that address significant unmet medical needs."

Financial Results for the Nine Months Ended September 30, 2012

Total revenue for the nine months ended September 30, 2012 was $1.7 million compared to $1.3 million in the same period in 2011. Product revenue from the BGM Galectin-3 test was $1.6 million in the nine months ended September 2012, compared to $0.1 million in the same period in 2011. Service revenue from collaborations decreased to $0.2 million in the nine months ended September 30, 2012 from $1.1 million in the corresponding period in 2011 as the Company focused its efforts on the commercialization of the BGM Galectin-3 test.

Operating expenses for the first nine months of 2012 were $21.9 million compared with operating expenses for the comparable period in 2011 of $14.0 million. This increase in operating expenses included higher research and development investments of $1.7 million primarily related to the BGM Galectin-3 and CardioSCORE test programs and an increase in sales and marketing expenses of $3.7 million related primarily to commercialization of the BGM Galectin-3 test in the U.S. and European markets. General and administrative expenses increased $2.2 million, mainly from personnel related costs and public company related expenses.

Originally posted here:

BG Medicine Reports Third Quarter 2012 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today provided an update on its new commercial strategy to speed the adoption of its cardiovascular diagnostic tests -- the BGM Galectin-3(R) test and the CardioSCORETM test.

Under the plan announced today, BG Medicine has begun to build its own dedicated sales organization and has taken steps to open its own CLIA lab in order to play a more active role alongside its commercial partners in driving sales and marketing efforts. In addition, the company highlighted its new Galectin-3 promotion effort, and provided an update on the regulatory and commercial path forward for CardioSCORE.

"We have taken a series of important steps over the past year to realign BG Medicine into a more commercially-focused company, capable of playing a larger role in facilitating the market adoption of our innovative cardiovascular diagnostic tests," said Eric Bouvier, President and CEO of BG Medicine. "The steps outlined today represent the culmination of our efforts to transform BG Medicine. Taken together, these actions place us in a much stronger position to control our own destiny and drive our own commercial success."

Highlights of the new commercial strategy include:

In addition, the company announced a strategic reorganization in its research and development department, away from its previous focus on early stage discovery and toward a more commercially-oriented role in support of the BGM Galectin-3 and CardioSCORE tests in the marketplace. As a result of this reorganization, 11 positions in early discovery research have been eliminated, enabling the company to dedicate a greater share of its R&D budget to commercial support and market growth activities.

"The implementation of the aggressive new strategy announced today will be a critical driver in our ongoing transformation into a full-scale commercial organization," continued Mr. Bouvier. "This is an important time in the evolution of BG Medicine and we look forward to sharing our progress in our execution of this strategy with our shareholders."

About BG Medicine, Inc.

BG Medicine, Inc. (BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company's first commercialized product, the BGM Galectin-3(R) test for use in patients with chronic heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORETM test, a blood test designed to aid in the assessment of an individual's risk for near-term major cardiovascular events. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

See the original post here:

BG Medicine Outlines New Commercial Strategy